Evaxion A (EVAX) Return on Capital Employed (2021 - 2025)
Evaxion A's (EVAX) quarterly Return on Capital Employed came in at 56.97% in Q4 2025, up 24.43% on a QoQ basis from 75.39% in Q2 2025.
Evaxion A (EVAX) Return on Capital Employed (2021 - 2025) Analysis & Trends
Evaxion A (EVAX) has 5 years of Return on Capital Employed data on file, last reported at 56.97% in Q4 2025.
- Quarterly Return on Capital Employed changed N/A year-over-year to 56.97% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 56.97% (changed N/A YoY) and the FY2025 annual result came in at 57.04%, up 12005.0% from the prior year.
- Return on Capital Employed advanced to 56.97% in Q4 2025, from 75.39% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 56.97% in Q4 2025 to a low of 501.94% in Q2 2024.
- A 5-year average of 184.68% and a median of 141.75% in 2021 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2024 — Return on Capital Employed sank 33167 bps — and 2025, when it soared 42655 bps.
- Tracing EVAX's Return on Capital Employed over 5 years: stood at 155.34% in 2021, then climbed by 22 bps to 120.47% in 2022, then slumped by 248 bps to 418.79% in 2023, then declined by 20 bps to 501.94% in 2024, then soared by 89 bps to 56.97% in 2025.
- The last three Return on Capital Employed figures came in at 56.97% (Q4 2025), 75.39% (Q2 2025), and 501.94% (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 26.09% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -50.93% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 7.88% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -6.85% |
| 10 | Evaxion A | 26.86 Mn | 26.86 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -56.97% |
| Jun 30, 2025 | -75.39% |
| Jun 30, 2024 | -501.94% |
| Dec 31, 2023 | -418.79% |
| Jun 30, 2023 | -170.27% |
| Dec 31, 2022 | -120.47% |
| Jun 30, 2022 | -116.17% |
| Mar 31, 2022 | -123.65% |
| Dec 31, 2021 | -155.34% |
| Sep 30, 2021 | -182.74% |
| Jun 30, 2021 | -128.15% |
| Mar 31, 2021 | -166.28% |